文献速递炎症性肠病

系统综述与荟萃分析:炎症性肠病治疗对血脂水平的影响

Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
PubMed 文献 · Aliment Pharmacol Ther · 2021-08-28

该系统综述与荟萃分析汇总11项研究共1663例患者,评估不同炎症性肠病(IBD)药物类别对血脂谱的影响。结果显示,诱导治疗期糖皮质激素使总胆固醇升高+1.19 mmol/L(95%CI +0.52至+2.59),托法替尼升高+0.66 mmol/L(95%CI +0.42至+0.79),而抗TNFα治疗未见显著升高(-0.11 mmol/L,95%CI -0.26至+0.36)。维持治疗期观察到相似差异,疗效与年龄相关。

要点

  • 糖皮质激素诱导治疗显著升高总胆固醇(+1.19 mmol/L)。
  • 托法替尼诱导治疗亦升高总胆固醇(+0.66 mmol/L)。
  • 抗TNFα治疗未观察到总胆固醇显著升高。

核心结论

  • 总胆固醇升高在糖皮质激素治疗中最明显,其次为托法替尼,抗TNFα未观察到升高。
  • IBD治疗相关的总胆固醇变化是否影响心血管风险需进一步研究。

研究设计与样本

  • 系统文献检索随机对照试验和观察性队列研究,评估IBD治疗诱导期(≤10周)和维持期(>10周)前后的血脂水平。
  • 11项研究(1663例患者)数据采用随机效应模型合并。
  • 6项研究(1211例患者)有个体数据,采用线性混合模型分析患者和疾病特征对总胆固醇治疗效应的影响。

主要发现

  • 诱导治疗期糖皮质激素使总胆固醇升高+1.19 mmol/L(95%CI +0.52至+2.59)。
  • 诱导治疗期托法替尼使总胆固醇升高+0.66 mmol/L(95%CI +0.42至+0.79)。
  • 抗TNFα治疗未显著升高总胆固醇(-0.11 mmol/L,95%CI -0.26至+0.36)。
  • 维持治疗期观察到相似差异。
  • 治疗效应与年龄显著相关,与其他因素无关;血脂变化与CRP变化呈负相关但不受其修饰。

临床怎么用

  • 对接受糖皮质激素或托法替尼治疗的IBD患者,可关注总胆固醇水平变化。
  • 抗TNFα治疗未观察到总胆固醇显著升高。

局限性

  • 总胆固醇变化与IBD治疗相关的心血管风险影响尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increase in lipid levels associated with the treatment of inflammatory bowel disease (IBD) has previously been reported. However, it is unknown if this effect is similar for all IBD drug classes. AIM: To precisely assess the effect of different IBD drug classes on lipid profiles METHODS: We performed a systematic literature search of randomised controlled trials and observational cohort studies that assessed lipid levels before and after induction (≤10 weeks) and maintenance (>10 weeks) of IBD treatment. Data of 11 studies (1663 patients) were pooled using random effects models. The influence of patient and disease characteristics on treatment effects on total cholesterol levels was analysed in 6 studies (1211 patients) for which individual data were available, using linear mixed models. RESULTS: A statistically significant increase in total cholesterol was observed after induction treatment with corticosteroids (+1.19 mmol/L, 95% confidence interval [CI95 ] +0.52 to +2.59), and tofacitinib (+0.66 mmol/L, CI95 +0.42 to +0.79), but not after anti-TNFα treatment (-0.11 mmol/L, CI95 -0.26 to +0.36 mmol/L). Similar differences were observed after maintenance treatment. Treatment effects were significantly related to age, but not with other factors. Lipid changes were inversely correlated with but not modified by CRP changes. CONCLUSIONS: Increase in total cholesterol levels was strongest for corticosteroids followed by tofacitinib but was not observed for anti-TNFα agents. Whether total cholesterol change associated with IBD treatment has an effect on cardiovascular risk requires further study.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sleutjes JAM, Roeters van Lennep JE, Boersma E, et al. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther. 2021. PMID: 34453860. doi:10.1111/apt.16580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。